山外山(688410) - 2025 Q4 - 年度业绩

Financial Performance - The total operating revenue for 2025 reached ¥806.82 million, an increase of 42.23% compared to the previous year[3] - The net profit attributable to the parent company was ¥143.12 million, reflecting a growth of 101.89% year-on-year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was ¥137.99 million, up 141.34% from the previous year[3] - Basic earnings per share increased to ¥0.4456, a rise of 100.99% compared to the same period last year[3] Assets and Equity - The total assets at the end of the reporting period were ¥2,332.17 million, a 15.94% increase from the beginning of the period[5] - The equity attributable to the parent company was ¥1,776.18 million, growing by 5.28% from the start of the period[5] Profitability and Market Position - The gross profit margin improved due to a decrease in unit fixed costs as production volume increased, enhancing overall profitability[5] - The company maintained its position as a leading domestic blood purification equipment manufacturer, benefiting from technological advantages and strong brand effects[6] - The sales revenue of self-produced blood purification consumables significantly increased during the reporting period[6] Reporting Accuracy - There are no major uncertainties affecting the accuracy of the performance report as of the announcement date[7]